Traitement du cancer non musculo invasif de la vessie par administration intravesicale de Ty21a.

Biological: Ty21a

Inclusion Criteria:

- Patients with an intermediary or low risk of progression of bladder cancer (according
to an EORTC score and clinical considerations) and thus not requiring BCG
immunotherapy will be included after a transurethral resection of the bladder tumor
(TURBT). Male and Female patients aged > 18yrs, with a Karnofsky performance status of
60% or more, sero-negative for HIV, HBV and HCV and with laboratory parameters for
vital function in the normal range or with abnormalities without clinical significance
may be included.

Exclusion Criteria:

- Patients with NMIBC that require BCG treatments or with muscle-invasive bladder
cancer, sero-positive for HIV, HBV and HCV or with other serious illnesses (e.g.,
serious infections requiring antibiotics, bleeding disorders, autoimmune disease),
will be excluded.